Myasthenia Gravis

Immunology·MeSH: Myasthenia Gravis

Prevalence

20.0 / 100K

Incidence

1.7 / 100K/yr

42 drugs in development·25 companies·18 clinical trials

Drug Pipeline by Phase

Approved(2)

Drug	Company
pyridostigmine	Amneal Pharmaceuticals, Inc. (AMRX)
Ultomiris	Xencor Inc (XNCR)

Phase 3(18)

Drug	Company
Batoclimab 340 mg SC bi-weekly	Immunovant, Inc. (IMVT)
Batoclimab 340 mg SC weekly	Immunovant, Inc. (IMVT)
Batoclimab 680 mg SC weekly	Immunovant, Inc. (IMVT)
claseprubart	Dianthus Therapeutics, Inc. /DE/ (DNTH)
descartes-08	Cartesian Therapeutics, Inc. (RNAC)
DNTH103	Dianthus Therapeutics, Inc. /DE/ (DNTH)
efgartigimod	GH Research PLC (GHRS)
Efgartigimod	Crinetics Pharmaceuticals, Inc. (CRNX)
hbm9161	Q BioMed Inc. (QBIO)
Iptacopan	Novartis AG (NVS)
nipocalimab	GH Research PLC (GHRS)
nipocalimab sc-liv	GH Research PLC (GHRS)
rozanolixizumab	POINT Biopharma Global Inc. (PNT)
telitacicept	Vor Biopharma Inc. (VOR)
tolebrutininb	Sanofi (SNY)
zilucoplan	GT Biopharma, Inc. (GTBP)
zilucoplan	RA PHARMACEUTICALS, INC. (RARX)
zilucoplan xr	RA PHARMACEUTICALS, INC. (RARX)

Phase 2(5)

Drug	Company
IMVT-1402	Immunovant, Inc. (IMVT)
iptacopan	Novartis AG (NVS)
m281	MOMENTA PHARMACEUTICALS INC (MNTA)
rese-cel	Cabaletta Bio, Inc. (CABA)
rozanolixizumab	GT Biopharma, Inc. (GTBP)

Phase 1(3)

Drug	Company
CABA-201	Filana Therapeutics Inc. (FLNA)
povetacicept	VERTEX PHARMACEUTICALS INC / MA (VRTX)
rese-cel (resecabtagene autoleucel)	Cabaletta Bio, Inc. (CABA)

Preclinical(1)

Drug	Company
rpi-78m	NUTRA PHARMA CORP (NPHC)

Phase 1/Phase 2(4)

Drug	Company
aritinercept	Aurinia Pharmaceuticals Inc. (AUPH)
MuSK-CAART	Cabaletta Bio, Inc. (CABA)
ytb323	Novartis AG (NVS)
YTB323	Novartis AG (NVS)

Phase 2/Phase 3(5)

Drug	Company
CABA-201	Cabaletta Bio, Inc. (CABA)
imvt-1402	Roivant Sciences Ltd. (ROIV)
kyv-101	Kyverna Therapeutics, Inc. (KYTX)
standard lymphodepletion regimen	Kyverna Therapeutics, Inc. (KYTX)
zilucoplan	POINT Biopharma Global Inc. (PNT)

Phase 4(4)

Drug	Company
Efgartigimod	ARGENX SE (ARGX)
Efgartigimod PH20 SC	ARGENX SE (ARGX)
ravulizumab	ALEXION PHARMACEUTICALS, INC. (ALXN)
Ravulizumab	ASTRAZENECA PLC (AZN)

BioSniper tracks 42 drugs in development for Myasthenia Gravis across 25 companies.

There are 18 clinical trials targeting Myasthenia Gravis tracked by BioSniper.

The estimated prevalence of Myasthenia Gravis is approximately 20.0 per 100,000 population.

Full trial data, competitive analysis, and AI-powered pipeline tracking.